Saccharomyces Boulardii

McFarland LV et al. • Frontiers in cellular and infection microbiology (2025)

“S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China.”

Key Findings:

S. boulardii CNCM I-745 was found to significantly reduce the duration of PAGE (SMD=-1.63 days, 95% CI -2.08, -1.18), improve the total effectiveness rating (RR=1.22, 95% CI 1.16, 1.28) and significantly more participants were cured (RR=1.47, 95% CI 1.30, 1.67).
The finding that S. boulardii significantly reduced the levels of two pro-inflammatory cytokines (TNF-α and IL8) has not been reported in previous meta-analyses of PAGE.
S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China.

📚meta-analysisn=5036

Li M et al. • Frontiers in cellular and infection microbiology (2025)

“S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.”

Key Findings:

S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Further research warranted to confirm findings

📚meta-analysisn=2021

Li Z et al. • Nutrients (2021)

“To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.”

Key Findings:

Saccharomyces boulardii [Odds ratio (OR) = 0.22; 95%CI, 0.11, 0.41] and Lactobacillus reuteri (OR = 0.23; 95%CI, 0.090, 0.60) significantly reduced the risk of diarrhea lasting ≥2 days when compared with placebo or no treatment, with moderate evidence.
To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.
Further research warranted to confirm findings

📚meta-analysisn=12127

Collinson S et al. • The Cochrane database of systematic reviews (2020)

“Probiotics probably make little or no difference to the number of people who have diarrhoea lasting 48 hours or longer, and we are uncertain whether probiotics reduce the duration of diarrhoea.”

Key Findings:

Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Effect size was similar and marked heterogeneity persisted in pre-specified subgroup analyses of the primary outcomes that included all studies.
In six trials (433 participants) of Lactobacillus reuteri, there was consistency amongst findings (I² = 0%), but risk of bias was present in all included studies.
In addition, there were no clear differences in effect size for the primary outcomes in post hoc analyses according to decade of publication of studies and whether or not trials had been registered.

📚meta-analysisn=2871

Compare with Others Find Based on Your Goals

Rahman MN et al. • Gut microbes (2024)

“Protocol registration: PROSPERO (ID = CRD42021276045).”

Key Findings:

This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
The persistence of pathogenic bacteria after treatment was 22%(probiotics) and 30.8%(placebo).
The pooled odds ratio was 0.59(95% CI:0.43-0.81), favoring probiotics with moderate certainty (p = 0.0001) and low heterogeneity (I2 = 49.2%, p = 0.0001).
In subgroup, C. difficile showed the highest decolonization (82.4%) in probiotics group.

View all 39+ studies

What would you like to do next?

Related Supplements

Pro9.0

Probiotics

Live microorganisms where strain selection determines outcome — Lactobacillus and Bifidobacterium strains best studied for gut, immune, and mood.

Lgn9.0

L-Glutamine

Primary fuel for intestinal and immune cells — becomes conditionally essential during stress, illness, or intense training.

Clm7.5

Colostrum

First milk rich in immunoglobulins, growth factors, and antimicrobial compounds that supports gut health, immunity, and recovery.

LF7.5

Lactoferrin

A multifunctional iron-binding glycoprotein from milk with broad antimicrobial, anti-inflammatory, and immune-modulating properties.

Sb9.0

Saccharomyces Boulardii

probiotic

Saccharomyces boulardii

Antibiotic-resistant probiotic yeast ideal for preventing traveler's diarrhea and protecting gut flora during antibiotic therapy.

immunitygut healthprobioticyeastdiarrhea

39+ studies

Evidence

Reviewed 19 days ago

high

Safety

250-500mg (5-10 billion CFU) daily

Dose

1-4 weeks

Time to Effect

Capsules (lyophilized)

Best Form

Mechanisms of Action

🛡️

Pathogen Binding

Binds to harmful bacteria and removes them

⚖️

Immune Modulation

Balances intestinal immune response

🧱

Gut Barrier Support

Helps maintain intestinal barrier integrity

Biological PathwayBeta

How Saccharomyces Boulardii works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.

Supplement

Molecular Target

Biological Process

Health Outcome

Strong

Moderate

Emerging

strong

moderate

emerging

Tap node to isolate • Pinch to zoom • Tap edge for research

Recommended Dose

250-500mg (5-10 billion CFU) daily

250mg1000mg

Loading: For acute diarrhea, may use 500mg 2x daily

Optimal Timing

With or without food
At least 2 hours away from antifungals

Can be taken without food

Available Forms

Form	Type
💊Capsules (lyophilized)	Recommended
🧪Powder	Alternative
💊Sachets	Alternative

Look for products with verified CFU counts. CNCM I-745 is the most researched strain (Florastor brand).

Duration

Minimum: 1 weeks

Optimal: 4 weeks

Cycling: Not required

Note: As a yeast, it's not killed by antibiotics. Start 2 days before travel for prevention. Continue 1 week after antibiotics finish.

🛡️

Diarrhea Prevention

Prevents antibiotic-associated and traveler's diarrhea

📅 During use

75% of users notice thispositive

⚡

Acute Diarrhea Treatment

Reduces duration of acute infectious diarrhea

⚡ 1-3 days

70% of users notice thispositive

🔄

Gut Microbiome Support

Helps restore healthy gut flora after antibiotics

⏱️ 1-2 weeks

65% of users notice thispositive

High SafetyMax safe dose: 1g/day commonly used

🔴

Immunocompromised

Avoid; risk of fungemia

🟢

Children

Well-studied and safe for pediatric diarrhea

Who Should NOT Take This

Central venous catheter (risk of fungemia)
Severely immunocompromised
ICU patients

Drug Interactions

Antifungalsmoderate

Antifungals will kill S. boulardii - separate by 2+ hours

Possible Side Effects

Gas/bloating

milduncommon

Tip: Usually transient

Warnings

Do not use with central venous catheters
Avoid in severely immunocompromised patients

⟡ Bacterial Probiotics

complementary

Can be combined with bacterial probiotics

Comprehensive gut flora support

Top studies from 39+ peer-reviewed papers

📚meta-analysisn=1125

McFarland LV et al. • Frontiers in cellular and infection microbiology (2025)

“S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China.”

Key Findings:

S. boulardii CNCM I-745 was found to significantly reduce the duration of PAGE (SMD=-1.63 days, 95% CI -2.08, -1.18), improve the total effectiveness rating (RR=1.22, 95% CI 1.16, 1.28) and significantly more participants were cured (RR=1.47, 95% CI 1.30, 1.67).
The finding that S. boulardii significantly reduced the levels of two pro-inflammatory cytokines (TNF-α and IL8) has not been reported in previous meta-analyses of PAGE.
S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China.

📚meta-analysisn=5036

Li M et al. • Frontiers in cellular and infection microbiology (2025)

“S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.”

Key Findings:

S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Further research warranted to confirm findings

📚meta-analysisn=2021

Li Z et al. • Nutrients (2021)

“To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.”

Key Findings:

Saccharomyces boulardii [Odds ratio (OR) = 0.22; 95%CI, 0.11, 0.41] and Lactobacillus reuteri (OR = 0.23; 95%CI, 0.090, 0.60) significantly reduced the risk of diarrhea lasting ≥2 days when compared with placebo or no treatment, with moderate evidence.
To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.
Further research warranted to confirm findings

📚meta-analysisn=12127

Collinson S et al. • The Cochrane database of systematic reviews (2020)

“Probiotics probably make little or no difference to the number of people who have diarrhoea lasting 48 hours or longer, and we are uncertain whether probiotics reduce the duration of diarrhoea.”

Key Findings:

Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Effect size was similar and marked heterogeneity persisted in pre-specified subgroup analyses of the primary outcomes that included all studies.
In six trials (433 participants) of Lactobacillus reuteri, there was consistency amongst findings (I² = 0%), but risk of bias was present in all included studies.
In addition, there were no clear differences in effect size for the primary outcomes in post hoc analyses according to decade of publication of studies and whether or not trials had been registered.

📚meta-analysisn=2871

Compare with Others Find Based on Your Goals

Rahman MN et al. • Gut microbes (2024)

“Protocol registration: PROSPERO (ID = CRD42021276045).”

Key Findings:

This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
The persistence of pathogenic bacteria after treatment was 22%(probiotics) and 30.8%(placebo).
The pooled odds ratio was 0.59(95% CI:0.43-0.81), favoring probiotics with moderate certainty (p = 0.0001) and low heterogeneity (I2 = 49.2%, p = 0.0001).
In subgroup, C. difficile showed the highest decolonization (82.4%) in probiotics group.

View all 39+ studies

What would you like to do next?

Related Supplements

Pro9.0

Probiotics

Live microorganisms where strain selection determines outcome — Lactobacillus and Bifidobacterium strains best studied for gut, immune, and mood.

Lgn9.0

L-Glutamine

Primary fuel for intestinal and immune cells — becomes conditionally essential during stress, illness, or intense training.

Clm7.5

Colostrum

First milk rich in immunoglobulins, growth factors, and antimicrobial compounds that supports gut health, immunity, and recovery.

LF7.5

Lactoferrin